RCS - Solvonis Therapeutic - Proactive Investors interview with CEO

Solvonis TherapeuticsAnnouncement

21/01/2025 14:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250121:nRSU1651Ua&default-theme=true

RNS Number : 1651U  Solvonis Therapeutics PLC  21 January 2025

RNS Reach - non-regulatory announcement

21 January 2025

Solvonis Therapeutics plc

("Solvonis Therapeutics" or the "Company")

 

Proactive Investors interview with CEO

 

Solvonis Therapeutics  (LON: SVNS), an innovative biotechnology company
co-developing therapeutics for mental health disorders, announces an
interview on Proactive Investors with Anthony Tennyson, CEO of the Company.
The interview with Anthony Tennyson can be viewed now at
https://www.proactiveinvestors.co.uk/companies/news/1064736/solvonis-therapeutics-says-fda-supports-phase-2b-for-awkn-002-candidate-1064736.html.

 

Enquiries:

 

Solvonis Therapeutics plc

Anthony Tennyson, CEO & Executive Director

Email: anthony@solvonis.com

 

Allenby Capital (Financial Adviser and Broker) +44 (0) 20 3328 5656

Nick Naylor / Liz Kirchner (Corporate Finance) | Guy McDougall (Sales)

 

 

About Solvonis Therapeutics plc

 

Solvonis Therapeutics plc is an innovative biotechnology company focused on
developing intellectual property relating to the treatment of mental health
and substance use disorders, and the co-development of therapeutics for mental
health disorders.  Our mission is to improve outcomes for individuals
suffering from these conditions, with an initial focus on trauma-related
mental health disorders, such as PTSD, which affected approximately 13 million
adults in the U.S. in 2020, with the Company estimating a current affected
population of 20 million across the US, UK and key EU markets.

 

For more information, please visit www.graft polymer.co.uk and also
www.solvonis.com

 

About Reach announcements

This is an RNS Reach announcement. Reach is an investor communication service
aimed at assisting listed and unlisted (including AIM quoted) companies to
distribute media only / non-regulatory news releases into the public domain.
Information required to be notified under the AIM Rules for Companies, Market
Abuse Regulation or other regulation would be disseminated as an RNS
regulatory announcement and not on Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAPPURPGUPAGCG